In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 20.31 below Structure Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Quick Ratio than Structure Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 179, from total ranking in the first quarter 2026 at 253.

Explain Quick Ratio?
How much Cash & cash equivalents GPCR�s has?
What are GPCR�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GPCR Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	353.48 %	56.18 %	75.69 %	72.06 %	-35.66 %
Y / Y Cash & cash equivalent Change	70.72 %	74.28 %	63.69 %	-12.7 %	-15.17 %
Quick Ratio MRQ	20.31	25.59	22.85	13.89	53.95
GPCR's Total Ranking	# 179	# 253	# 375	# 108	# 221
Seq. Current Liabilities Change	16.02 %	-9.96 %	10.01 %	294.59 %	-60.04 %
Seq. Cash & cash equivalent Change	-7.94 %	0.85 %	80.99 %	1.59 %	-6.02 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 37
Healthcare Sector	# 56
Overall Market	# 218

Quick Ratio Statistics
High	Average	Low
53.95	26.45	9.24
(Jun 30 2025)		(Dec 31 2022)

Financial Statements
Structure Therapeutics Inc 's Current Liabilities	$ 66 Millions	Visit GPCR's Balance sheet
Structure Therapeutics Inc 's Cash & cash equivalent	$ 1,343 Millions	Visit GPCR's Balance sheet
Source of GPCR's Sales		Visit GPCR's Sales by Geography

Cumulative Structure Therapeutics Inc 's Quick Ratio

GPCR's Quick Ratio for the trailling 12 Months

GPCR Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	102.38 %	49.59 %	48.55 %	37.34 %	31.07 %
Y / Y Cash & cash equivalent TTM Growth	47.46 %	26.03 %	22.33 %	20.38 %	68.06 %
Quick Ratio TTM	20.69	23.34	22.51	22.86	28.39
Total Ranking TTM	# 150	# 165	# 138	# 102	# 147
Seq. Current Liabilities TTM Growth	26.79 %	11.93 %	18.85 %	19.99 %	-6.28 %
Seq. Cash & cash equivalent TTM Growth	12.39 %	16.07 %	17.02 %	-3.4 %	-3.95 %

Quick ratio ranking by company, industry and sector >> Back to GPCR Financial Strength Comparisons >> Go to Compare GPCR Quick Ratio to its Competitors

News about Structure Therapeutics Inc Quick Ratio

Structure Therapeutics Inc. Raises $547.4 Million in Public Offering, Faces Quick Ratio Challenges

Structure Therapeutics Inc. recently announced the successful closing of its upsized underwritten public offering, which saw the sale of 10,427,017 American depositary shares (ADSs) at a price of $52.50 per ADS. This resulted in aggregate gross proceeds of approximately $547.4 million for the company.
However, despite a sequential decrease in current liabilities, the company s Quick Ratio deteriorated to 18.5 in the first quarter of 2024, below the industry average of 27.15. In comparison to other companies within the industry, Structure Therapeutics Inc. now ranks lower than it did in the previous quarter, at 100.
Looking at the trailing twelve months basis, the decrease in current liabilities led to a cumulative Quick Ratio of 18, still above the industry average. However, when compared to other companies in the industry, Structure Therapeutics Inc. falls behind with only 231 outperforming companies in terms of Quick Ratio.
While the company has seen an improvement in its overall ranking for Quick Ratio over the past twelve months, the recent figures suggest there is room for improvement. It will be interesting to see how Structure Therapeutics Inc. utilizes the proceeds from the public offering to strengthen its financial position and potentially improve its Quick Ratio in the future

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2026 to $66.11 millions, cumulative Quick Ratio decreased to 20.69 above the GPCR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 410 other companies have achieved higher Quick Ratio than Structure Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2138.

Explain Quick Ratio?
How much Cash & cash equivalents GPCR�s has?
What are GPCR�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 411
Healthcare Sector	# 832
Within the Market	# 179

trailing twelve months Quick Ratio Statistics
High	Average	Low
10.5	7.5	3.82
(Jun 30 2026)		(Mar 31 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Avalyn Pharma Inc	49.93	$ 539.733 Millions	$ 10.809 Millions
Pasithea Therapeutics Corp	49.76	$ 91.464 Millions	$ 1.838 Millions
Disc Medicine Inc	44.03	$ 1,336.770 Millions	$ 30.360 Millions
Trevi Therapeutics Inc	36.50	$ 318.870 Millions	$ 8.736 Millions
Design Therapeutics Inc	35.76	$ 401.889 Millions	$ 11.240 Millions
Mineralys Therapeutics Inc	34.87	$ 673.704 Millions	$ 19.319 Millions
Praxis Precision Medicines Inc	34.32	$ 1,683.790 Millions	$ 49.058 Millions
Agios Pharmaceuticals Inc	33.94	$ 2,383.112 Millions	$ 70.217 Millions
Mbx Biosciences Inc	33.10	$ 783.099 Millions	$ 23.660 Millions
Xbiotech Inc	32.67	$ 109.528 Millions	$ 3.353 Millions
Avalo Therapeutics Inc	31.89	$ 787.143 Millions	$ 24.682 Millions
Fulcrum Therapeutics Inc	30.96	$ 318.840 Millions	$ 10.298 Millions
Climb Bio Inc	30.86	$ 183.123 Millions	$ 5.934 Millions
Indaptus Therapeutics Inc	29.61	$ 15.554 Millions	$ 0.525 Millions
Crinetics Pharmaceuticals Inc	29.41	$ 2,350.275 Millions	$ 79.915 Millions
Spyre Therapeutics Inc	28.48	$ 1,100.000 Millions	$ 38.620 Millions
Curanex Pharmaceuticals Inc	28.17	$ 2.938 Millions	$ 0.104 Millions
Onkure Therapeutics Inc	28.04	$ 186.284 Millions	$ 6.643 Millions
Ligand Pharmaceuticals Incorporated	27.33	$ 1,277.438 Millions	$ 46.736 Millions
Shattuck Labs Inc	26.94	$ 208.300 Millions	$ 7.731 Millions
Cryoport inc	26.87	$ 785.860 Millions	$ 29.244 Millions
Roivant Sciences Ltd	26.82	$ 7,607.076 Millions	$ 283.603 Millions
Palvella Therapeutics Inc	26.23	$ 313.381 Millions	$ 11.947 Millions
Upstream Bio Inc	26.16	$ 261.307 Millions	$ 9.988 Millions
Rallybio Corporation	26.02	$ 92.800 Millions	$ 3.567 Millions
Assembly Biosciences Inc	25.95	$ 608.475 Millions	$ 23.445 Millions
Arbutus Biopharma Corp	25.84	$ 92.625 Millions	$ 3.585 Millions
Immix Biopharma Inc	25.49	$ 238.715 Millions	$ 9.364 Millions
Boundless Bio Inc	25.00	$ 194.230 Millions	$ 7.768 Millions
Sionna Therapeutics Inc	24.88	$ 268.300 Millions	$ 10.782 Millions

Date modified: 2026-09-08T01:17:30+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.